Selected research
Market Structure
Global Pentavalent Antimonials Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Pentavalent Antimonials market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Pentavalent Antimonials is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Pentavalent Antimonials is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Pentavalent Antimonials is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Pentavalent Antimonials is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Pentavalent Antimonials include Xinhua Pharm, Sanofi, GlaxoSmithKline, Science Direct, Maiden Pharmaceuticals, Bristol-Myers Squibb and Albert David, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Pentavalent Antimonials market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Pentavalent Antimonials and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Pentavalent Antimonials sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pentavalent Antimonials market size, projected growth trends, production technologies, key applications, and end-use industries.
Pentavalent Antimonials Segment by Company
Xinhua Pharm
Sanofi
GlaxoSmithKline
Science Direct
Maiden Pharmaceuticals
Bristol-Myers Squibb
Albert David
Pentavalent Antimonials Segment by Type
Sodium Stibogluconate
Meglumine Antimoniate
Pentavalent Antimonials Segment by Application
Retail Pharmacies
Hospitals Pharmacies
Online Pharmacies
Pentavalent Antimonials Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pentavalent Antimonials market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pentavalent Antimonials and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pentavalent Antimonials.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Pentavalent Antimonials market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pentavalent Antimonials manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pentavalent Antimonials in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Pentavalent Antimonials in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Sodium Stibogluconate
- Meglumine Antimoniate
Applications
- Retail Pharmacies
- Hospitals Pharmacies
- Online Pharmacies
Companies covered
- Xinhua Pharm
- Sanofi
- GlaxoSmithKline
- Science Direct
- Maiden Pharmaceuticals
- Bristol-Myers Squibb
- Albert David
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Pentavalent Antimonials Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Pentavalent Antimonials Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Pentavalent Antimonials Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Pentavalent Antimonials Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Pentavalent Antimonials Market Dynamics
- 2.1 Pentavalent Antimonials Industry Trends
- 2.2 Pentavalent Antimonials Industry Drivers
- 2.3 Pentavalent Antimonials Industry Opportunities and Challenges
- 2.4 Pentavalent Antimonials Industry Restraints
3 Pentavalent Antimonials Market by Manufacturers
- 3.1 Global Pentavalent Antimonials Revenue by Manufacturers (2021-2026)
- 3.2 Global Pentavalent Antimonials Sales by Manufacturers (2021-2026)
- 3.3 Global Pentavalent Antimonials Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Pentavalent Antimonials Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Pentavalent Antimonials Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Pentavalent Antimonials Manufacturers, Product Type & Application
- 3.7 Global Pentavalent Antimonials Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Pentavalent Antimonials Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Pentavalent Antimonials Players Market Share by Revenue in 2025
- 3.8.3 2025 Pentavalent Antimonials Tier 1, Tier 2, and Tier 3
4 Pentavalent Antimonials Market by Type
- 4.1 Pentavalent Antimonials Type Introduction
- 4.1.1 Sodium Stibogluconate
- 4.1.2 Meglumine Antimoniate
- 4.2 Global Pentavalent Antimonials Sales by Type
- 4.2.1 Global Pentavalent Antimonials Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Pentavalent Antimonials Sales by Type (2021-2032)
- 4.2.3 Global Pentavalent Antimonials Sales Market Share by Type (2021-2032)
- 4.3 Global Pentavalent Antimonials Revenue by Type
- 4.3.1 Global Pentavalent Antimonials Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Pentavalent Antimonials Revenue by Type (2021-2032)
- 4.3.3 Global Pentavalent Antimonials Revenue Market Share by Type (2021-2032)
5 Pentavalent Antimonials Market by Application
- 5.1 Pentavalent Antimonials Application Introduction
- 5.1.1 Retail Pharmacies
- 5.1.2 Hospitals Pharmacies
- 5.1.3 Online Pharmacies
- 5.2 Global Pentavalent Antimonials Sales by Application
- 5.2.1 Global Pentavalent Antimonials Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Pentavalent Antimonials Sales by Application (2021-2032)
- 5.2.3 Global Pentavalent Antimonials Sales Market Share by Application (2021-2032)
- 5.3 Global Pentavalent Antimonials Revenue by Application
- 5.3.1 Global Pentavalent Antimonials Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Pentavalent Antimonials Revenue by Application (2021-2032)
- 5.3.3 Global Pentavalent Antimonials Revenue Market Share by Application (2021-2032)
6 Global Pentavalent Antimonials Sales by Region
- 6.1 Global Pentavalent Antimonials Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Pentavalent Antimonials Sales by Region (2021-2032)
- 6.2.1 Global Pentavalent Antimonials Sales by Region (2021-2026)
- 6.2.2 Global Pentavalent Antimonials Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Pentavalent Antimonials Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Pentavalent Antimonials Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Pentavalent Antimonials Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Pentavalent Antimonials Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Pentavalent Antimonials Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Pentavalent Antimonials Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Pentavalent Antimonials Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Pentavalent Antimonials Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Pentavalent Antimonials Revenue by Region
- 7.1 Global Pentavalent Antimonials Revenue by Region
- 7.1.1 Global Pentavalent Antimonials Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Pentavalent Antimonials Revenue by Region (2021-2026)
- 7.1.3 Global Pentavalent Antimonials Revenue by Region (2027-2032)
- 7.1.4 Global Pentavalent Antimonials Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Pentavalent Antimonials Revenue (2021-2032)
- 7.2.2 North America Pentavalent Antimonials Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Pentavalent Antimonials Revenue (2021-2032)
- 7.3.2 Europe Pentavalent Antimonials Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Pentavalent Antimonials Revenue (2021-2032)
- 7.4.2 Asia-Pacific Pentavalent Antimonials Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Pentavalent Antimonials Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Pentavalent Antimonials Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Xinhua Pharm
- 8.1.1 Xinhua Pharm Company Information
- 8.1.2 Xinhua Pharm Business Overview
- 8.1.3 Xinhua Pharm Pentavalent Antimonials Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Xinhua Pharm Pentavalent Antimonials Product Portfolio
- 8.1.5 Xinhua Pharm Recent Developments
- 8.2 Sanofi
- 8.2.1 Sanofi Company Information
- 8.2.2 Sanofi Business Overview
- 8.2.3 Sanofi Pentavalent Antimonials Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Sanofi Pentavalent Antimonials Product Portfolio
- 8.2.5 Sanofi Recent Developments
- 8.3 GlaxoSmithKline
- 8.3.1 GlaxoSmithKline Company Information
- 8.3.2 GlaxoSmithKline Business Overview
- 8.3.3 GlaxoSmithKline Pentavalent Antimonials Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 GlaxoSmithKline Pentavalent Antimonials Product Portfolio
- 8.3.5 GlaxoSmithKline Recent Developments
- 8.4 Science Direct
- 8.4.1 Science Direct Company Information
- 8.4.2 Science Direct Business Overview
- 8.4.3 Science Direct Pentavalent Antimonials Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Science Direct Pentavalent Antimonials Product Portfolio
- 8.4.5 Science Direct Recent Developments
- 8.5 Maiden Pharmaceuticals
- 8.5.1 Maiden Pharmaceuticals Company Information
- 8.5.2 Maiden Pharmaceuticals Business Overview
- 8.5.3 Maiden Pharmaceuticals Pentavalent Antimonials Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Maiden Pharmaceuticals Pentavalent Antimonials Product Portfolio
- 8.5.5 Maiden Pharmaceuticals Recent Developments
- 8.6 Bristol-Myers Squibb
- 8.6.1 Bristol-Myers Squibb Company Information
- 8.6.2 Bristol-Myers Squibb Business Overview
- 8.6.3 Bristol-Myers Squibb Pentavalent Antimonials Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Bristol-Myers Squibb Pentavalent Antimonials Product Portfolio
- 8.6.5 Bristol-Myers Squibb Recent Developments
- 8.7 Albert David
- 8.7.1 Albert David Company Information
- 8.7.2 Albert David Business Overview
- 8.7.3 Albert David Pentavalent Antimonials Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Albert David Pentavalent Antimonials Product Portfolio
- 8.7.5 Albert David Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Pentavalent Antimonials Value Chain Analysis
- 9.1.1 Pentavalent Antimonials Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Pentavalent Antimonials Production Mode & Process
- 9.2 Pentavalent Antimonials Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Pentavalent Antimonials Distributors
- 9.2.3 Pentavalent Antimonials Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst